Barclays PLC Grows Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Barclays PLC grew its holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 243.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,502 shares of the company’s stock after purchasing an additional 42,185 shares during the quarter. Barclays PLC owned about 0.11% of ALX Oncology worth $107,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Rhumbline Advisers increased its holdings in shares of ALX Oncology by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after buying an additional 5,360 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of ALX Oncology by 50.7% during the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after buying an additional 6,080 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology during the 2nd quarter worth approximately $63,000. Finally, Wellington Management Group LLP increased its holdings in shares of ALX Oncology by 15.2% during the 3rd quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock worth $305,000 after buying an additional 22,114 shares during the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a report on Wednesday, December 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. Finally, Jefferies Financial Group downgraded shares of ALX Oncology from a “buy” rating to a “hold” rating and dropped their target price for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

ALX Oncology Stock Down 9.4 %

ALX Oncology stock opened at $1.63 on Friday. ALX Oncology Holdings Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $17.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The firm has a 50 day moving average price of $1.61 and a 200 day moving average price of $2.43. The company has a market capitalization of $85.97 million, a PE ratio of -0.55 and a beta of 0.98.

Insiders Place Their Bets

In other ALX Oncology news, Director Rekha Hemrajani purchased 30,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the purchase, the director now directly owns 33,000 shares in the company, valued at approximately $51,150. The trade was a 1,000.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 14,443 shares of company stock worth $23,309 over the last 90 days. Corporate insiders own 33.40% of the company’s stock.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.